Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Enzobiotics
- Development stage
- Unknown
- Lead developer
- Mylin Biotech India
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Peptides, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Enzobiotics is an oral synbiotic therapeutic developed by Mylin Biotech (Mylin Holdings) for the treatment of Chronic Kidney Disease (CKD). The formulation is a combination of probiotics, prebiotics, and proteolytic enzymes (enzobiotics) delivered in an acid- and bile-resistant capsule. It targets the gut-kidney axis by shifting the intestinal microbiome from a dysbiotic state to a healthy one, thereby reducing the generation and systemic accumulation of protein-bound uremic toxins, specifically p-cresyl sulfate (PCS) and indoxyl sulfate (IS). These toxins are known to contribute to CKD progression and cardiovascular complications. By lowering toxin levels and systemic inflammatory markers such as IL-6 and TNF-α, Enzobiotics aims to slow the progression of CKD, delay the requirement for dialysis, and improve patient quality of life. The product is currently being evaluated in the EETOX study, a multicenter Phase 2/3 clinical trial, and is protected by patent no. 412644.
- Brand names
- Zavetox
- Other names
- Mylin synbioticEnzobioticSynbiotics
02
Targets
IS (Indoxyl sulfate)
Beyond the preview
Go deeper on Enzobiotics.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enzobiotics.